FDA Inspection 1118683 — Cdymax (India) Pharma Private Limited

Cdymax (India) Pharma Private Limited — FEI 3009882550

The FDA completed an inspection of Cdymax (India) Pharma Private Limited on Jan 31, 2020 in Bangalore. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Jan 31, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Bangalore (India)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.